Lyell Immunopharma, Inc.
LYEL · NASDAQ
Market closed$13.32$-0.570000 (-4.10%)After hours $13.60 · +2.10%
Key statistics
Previous close$13.89
Open$13.81
Day high$13.90
Day low$13.06
52-week high$45.00
52-week low$9.28
Market cap310.81M
Volume168.67K
Average volume150.33K
P/E ratio-0.97
Forward P/E—
EPS-13.80
Dividend yield0.00%
Market context
Why it moved
LYEL shares declined as selling pressure continued, exacerbated by a notable insider disposition of shares by major stakeholder Innovative Cellular Therapeutics Holdings, contributing to an over 11% drop in the stock over the past week.
What is happening
Recent company-specific developments and publisher coverage.
Ad Hoc News · July 3, 2026Lyell Immunopharma updates pipeline strategy as cell therapy field evolvesGlobeNewswire · June 25, 2026Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceStock Titan · June 12, 2026Over 100 lymphoma patients get CAR-T with no Grade 3+ CRSStock Titan · June 4, 2026Lyell CAR T study reports low-grade side effects in lymphomaGlobeNewswire · May 6, 2026Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026GlobeNewswire · February 12, 2026Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell LymphomaGlobeNewswire · November 10, 2025Lyell Immunopharma Acquires Exclusive Global Rights to aQuiver Quantitative · July 25, 2025Lyell Immunopharma, Inc. Secures $100 Million in Private Placement to Advance CAR T-Cell Therapy Trials Mt Newswire · July 13, 2026Lyell Immunopharma Files for Secondary Offering of Common Shares Benzinga · June 15, 2026Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target Benzinga · June 15, 2026Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target Benzinga · June 12, 2026Lyell Immunopharma Announces Data From Its Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-cell Lymphoma Shows Manufacturing Success Rate Of 97% Benzinga · June 8, 2026Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target Benzinga · June 8, 2026Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update Mt Newswire · June 8, 2026Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study Benzinga · June 8, 2026Lyell Immunopharma Issues LYL273 Safety Profile Update In Its Ongoing U.S. Phase 1 Clinical Trial In Patients With Relapsed Or Refractory Metastatic Colorectal Cancer